Clinical trial · no report yet · Phase 2
waveLINE-007
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- NCT05406401 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Interventions
- Zilovertamab Vedotin; Cyclophosphamide; Doxorubicin; Rituximab; Rituximab Biosimilar; Prednisone; Prednisolone
- Arms
- Zilovertamab Vedotin + R-CHP: Dose Escalation/Confirmation · Experimental
- Zilovertamab Vedotin + R-CHP: Efficacy Expansion · Experimental
- Enrollment
- 60 (estimated)
- Primary outcomes
- Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1
- Number of Participants Who Experienced At Least One AE
- Number of Participants Who Discontinued Study Treatment Due to an AE
- Complete Response Rate (CRR) per Lugano Response Criteria
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jul 14, 2022
- Primary completion
- Apr 26, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05406401 · updated Oct 15, 2024